Heparin Hanlim Special Precautions

An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing Heparin Hanlim. Periodic platelet counts, hematocrits and tests for occult blood in stool are recommended during the entire course heparin therapy. Bleeding control as bleeding test should be checked. If the administration be discontinued abruptly, blood clotting may occur. Heparin Hanlim should be administered very slowly. If blood clot occurs, the action of Heparin Hanlim may be reduced. When clinical circumstances require the reversal of heparinization, protamine sulfate (1% solution) will neutralize heparin sodium. The number of thrombocyte should be monitored during the entire course of heparin therapy. The administration should be promptly discontinued if patient develops = new thrombosis in association with thrombocytopenia.
Patients Who Have Increased Danger of Hemorrhage: Cardiovascular: Subacute bacterial endocarditis, severe hypertension, arthereosclerosis, increased permeability of peripheral vessel.
Hematologic: Hemophilia, thrombocytopenia, jaundice, purpura, weakness of peripheral vessel.
Gastrointestinal: Ulcerative lesion, colitis, swelling of intestine, gastrointestinal diverticulitis.
Gynecologic: Abortion, premature birth, menstruation, postpartum hemorrhage.
Other: Operation, postoperation, urinary tract hemorrhage, hemoptysis, severe diabetes mellitus.
Patients with impaired renal dysfunction; hemorrhage after use of Heparin Hanlim; consumption coagulopathy. Catarrh-inserted patients.
Use in pregnancy: Administer with caution in pregnant women in late trimester.
Use in children: Neonates, immature infants for this drug contains benzyl alcohol as preservative.